Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred Tax AssetsCurrent Deferred Tax AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOther Accumulated ExpensesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sagimet Biosciences (SGMT) Retained Earnings (2022 - 2026)

Sagimet Biosciences' Retained Earnings history spans 5 years, with the latest figure at -$357.0 million for Q1 2026.

  • Quarterly Retained Earnings fell 295140.5% to -$357.0 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$357.0 million through Mar 2026, down 295140.5% year-over-year, with the annual reading at -$346.3 million for FY2025, 150686.52% down from the prior year.
  • Retained Earnings came in at -$357.0 million for Q1 2026, down from -$346.3 million in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of $230000.0 in Q4 2024 to a low of -$357.0 million in Q1 2026.
  • The 5-year median for Retained Earnings is -$241.6 million (2023), against an average of -$199.8 million.
  • Year-over-year, Retained Earnings skyrocketed 666.67% in 2024 and then crashed 1408160.87% in 2025.
  • Sagimet Biosciences' Retained Earnings stood at -$221.9 million in 2022, then surged by 100.01% to $30000.0 in 2023, then surged by 666.67% to $230000.0 in 2024, then tumbled by 150686.52% to -$346.3 million in 2025, then decreased by 3.07% to -$357.0 million in 2026.
  • Per Business Quant, the three most recent readings for SGMT's Retained Earnings are -$357.0 million (Q1 2026), -$346.3 million (Q4 2025), and -$336.8 million (Q3 2025).